Baird Slashes Coherus Biosciences Share Price Target Over Influential Yusimry Sale and Intensified Oncology Focus
Monday, 1 July 2024, 08:33
Overview
Financial analyst Baird recently made a crucial decision regarding Coherus Biosciences, impacting the company's stock valuation.
Influence of Yusimry Sale
Baird's cut in Coherus' share price target is attributed to the consequential sale of Yusimry within the company's portfolio.
Shift to Oncology Focus
The intensified focus on oncology by Coherus Biosciences has played a significant role in Baird's downward revision of the share price target.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.